×
Harrow Common Stock Net 2010-2024 | HROW
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Harrow common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
Harrow Common Stock Net 2010-2024 | HROW
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Harrow common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$78.6B
Takeda Pharmaceutical (TAK)
$44.1B
Merck (MKKGY)
$21.2B
Astellas Pharma (ALPMY)
$20.4B
Sandoz Group AG (SDZNY)
$19.7B
United Therapeutics (UTHR)
$18B
Summit Therapeutics (SMMT)
$15.6B
Neurocrine Biosciences (NBIX)
$12.6B
Shionogi (SGIOY)
$12.5B
Catalent (CTLT)
$10.9B
Madrigal Pharmaceuticals (MDGL)
$7.7B
Jazz Pharmaceuticals (JAZZ)
$7.4B
Orion OYJ (ORINY)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.1B
Corcept Therapeutics (CORT)
$5.7B
Crinetics Pharmaceuticals (CRNX)
$4.8B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$2B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Ocular Therapeutix (OCUL)
$1.7B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
ARS Pharmaceuticals (SPRY)
$1.6B
Avadel Pharmaceuticals (AVDL)
$1.5B